CA3204401A1 - Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof - Google Patents
Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereofInfo
- Publication number
- CA3204401A1 CA3204401A1 CA3204401A CA3204401A CA3204401A1 CA 3204401 A1 CA3204401 A1 CA 3204401A1 CA 3204401 A CA3204401 A CA 3204401A CA 3204401 A CA3204401 A CA 3204401A CA 3204401 A1 CA3204401 A1 CA 3204401A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- isoindolin
- pyrimidin
- compound
- 6a1ky1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134747P | 2021-01-07 | 2021-01-07 | |
| US63/134,747 | 2021-01-07 | ||
| PCT/CA2022/050016 WO2022147622A1 (en) | 2021-01-07 | 2022-01-07 | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3204401A1 true CA3204401A1 (en) | 2022-07-14 |
Family
ID=82357069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3204401A Pending CA3204401A1 (en) | 2021-01-07 | 2022-01-07 | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240092763A1 (https=) |
| EP (1) | EP4277902A4 (https=) |
| JP (1) | JP2024502175A (https=) |
| CN (1) | CN116940565A (https=) |
| AU (1) | AU2022206470A1 (https=) |
| CA (1) | CA3204401A1 (https=) |
| WO (1) | WO2022147622A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102939283B1 (ko) * | 2022-05-03 | 2026-03-13 | 한국화학연구원 | 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| US20260085036A1 (en) * | 2022-09-12 | 2026-03-26 | Mihkal Gmbh | Novel nootropic prodrugs of henethylamine |
| KR20240156074A (ko) * | 2023-04-21 | 2024-10-29 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해제 및 이를 함유하는 항암용 조성물 |
| CN116947764B9 (zh) * | 2023-07-13 | 2025-07-25 | 特科罗生物科技(成都)有限公司 | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 |
| KR20250041906A (ko) * | 2023-09-19 | 2025-03-26 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1660458E (pt) * | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| CA2634646C (en) * | 2005-12-21 | 2012-04-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| ES2555803T3 (es) * | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| HUE030912T2 (en) * | 2008-02-15 | 2017-06-28 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases |
| MX353308B (es) * | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| JP5781943B2 (ja) * | 2009-01-21 | 2015-09-24 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体 |
| PH12012501556A1 (en) * | 2009-12-30 | 2012-10-22 | Arqule Inc | Substituted naphthalenyl-pyrimidine compounds |
| WO2012051587A1 (en) * | 2010-10-14 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in egfr-driven cancers |
| EP3789386A1 (en) * | 2017-01-26 | 2021-03-10 | Hanmi Pharm. Co., Ltd. | Pyrimidine compound and pharmaceutical use thereof |
| MX2021010323A (es) * | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
| WO2021239133A1 (zh) * | 2020-05-29 | 2021-12-02 | 南京正大天晴制药有限公司 | 作为axl抑制剂的嘧啶类化合物 |
-
2022
- 2022-01-07 WO PCT/CA2022/050016 patent/WO2022147622A1/en not_active Ceased
- 2022-01-07 JP JP2023541658A patent/JP2024502175A/ja active Pending
- 2022-01-07 AU AU2022206470A patent/AU2022206470A1/en not_active Abandoned
- 2022-01-07 CA CA3204401A patent/CA3204401A1/en active Pending
- 2022-01-07 CN CN202280019578.4A patent/CN116940565A/zh active Pending
- 2022-01-07 US US18/271,103 patent/US20240092763A1/en active Pending
- 2022-01-07 EP EP22736481.7A patent/EP4277902A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4277902A1 (en) | 2023-11-22 |
| WO2022147622A1 (en) | 2022-07-14 |
| EP4277902A4 (en) | 2024-12-18 |
| AU2022206470A9 (en) | 2024-09-26 |
| US20240092763A1 (en) | 2024-03-21 |
| CN116940565A (zh) | 2023-10-24 |
| AU2022206470A1 (en) | 2023-07-27 |
| JP2024502175A (ja) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3204401A1 (en) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof | |
| AU2009224546B2 (en) | Derivatives of tetrahydroquinoxaline urea, preparation thereof and therapeutic application thereof | |
| US7465737B2 (en) | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives | |
| RU2636589C2 (ru) | Аминопиримидиновые ингибиторы киназ | |
| US7713958B2 (en) | Compounds and compositions as protein kinase inhibitors | |
| AU2020226042B2 (en) | Novel heterotricyclic derivative compound and use of same | |
| CN110156787B (zh) | 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途 | |
| CA3038280A1 (en) | Heteroaryl derivatives as sepiapterin reductase inhibitors | |
| KR102680160B1 (ko) | 심부전의 치료를 위한 rock의 5원-아미노헤테로사이클 및 5,6- 또는 6,6-원 비시클릭 아미노헤테로시클릭 억제제 | |
| CA3073977A1 (en) | Inhibitors of wdr5 protein-protein binding | |
| WO2013013188A1 (en) | Heterocyclic protein kinase inhibitors | |
| EP4705281A1 (en) | Compounds for treating cancer | |
| EP2964223A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| AU2007338574A1 (en) | Tricyclic heteroaryl compounds useful as inhibitors of Janus kinase | |
| US20240025887A1 (en) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof | |
| CN115448921B (zh) | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 | |
| CA3116830A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| NZ568014A (en) | Substituted bicyclic pyrimidone derivatives | |
| NZ576773A (en) | Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives | |
| CA3151039A1 (en) | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | |
| CA3086362C (en) | Quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders | |
| EP2532664A1 (en) | Substituted indolo [2,3-a] quinolizines in the treatment of cancer | |
| HK40064179A (en) | Piperazine amide derivative, preparation method therefor, and use thereof in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |